No. They were particularly anxiety, and depression and neuropsychiatric symptoms. This again was based on a retrospective dataset, and thus was an opportunistic study. It was not targeted and defined. This is a piece of research that still needs to be carried out.
But I think that with the weight of that evidence, together with the evidence presented at the Senate inquiry, plus events that are occurring internationally around acceptance and acknowledgement of the impacts of mefloquine on veterans' mental health, and settled cases of litigation, I think there was probably a cumulative effect that suggested to the government this was a necessary process. As well, there were those individuals who are working inside the Department of Veterans' Affairs and Open Arms who were strongly supportive of this group of veterans and, more broadly, those veterans affected by brain injury of many different causes.